Riluzole - Aquestive Therapeutics
Alternative Names: AQST-117; Exservan; Riluzole oral soluble film; Riluzole OSFLatest Information Update: 07 Apr 2023
At a glance
- Originator MonoSol Rx
- Developer Aquestive Therapeutics; Mitsubishi Tanabe Pharma America
- Class Benzothiazoles; Neuroprotectants; Small molecules
- Mechanism of Action Excitatory amino acid antagonists; Glutamate release inhibitors; Voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Amyotrophic lateral sclerosis
Most Recent Events
- 31 Dec 2022 Registered for Amyotrophic lateral sclerosis in European Union prior to December 2022 (PO)
- 07 Mar 2022 Aquestive Therapeutics enters into licensing and supply agreement with Haisco Pharmaceutical Group for Riluzole for the treatment of amyotrophic lateral sclerosis in China
- 30 Jun 2021 Launched for Amyotrophic lateral sclerosis (Adjunctive treatment) in USA (PO)